SEC Company Response from Arcadia Biosciences, Inc. (RKDA) (CIK 0001469443) (RKDA) — Dec 18, 2019
Arcadia Biosciences, Inc. (RKDA) (CIK 0001469443)
Date: Dec. 18, 2019 · CIK: 0001469443 · Accession: 0001564590-19-046289
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235446
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Attention:Ada D. Sarmento Re: Arcadia Biosciences, Inc. Registration Statement on Form S-1 (No. 333-235446) Request for Acceleration
Dear Ms. Sarmento:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Arcadia Biosciences, Inc. hereby requests that the effective date of its Registration Statement on Form S-1 (File No. 333-235446) be accelerated so that the same will become effective at 4:00 p.m., Eastern Time, on Friday, December 20, 2019, or as soon thereafter as practicable.
If you have any questions regarding this request or the Registration Statement, please call our counsel Mike De Angelis of Weintraub Tobin, at (916) 558-6164.
Very truly yours,
Arcadia Biosciences, Inc.
Show Raw Text
CORRESP 1 filename1.htm rkda-corresp.htm Arcadia Biosciences, Inc. 202 Cousteau Place, Suite 200 Davis, CA 95618 December 18, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention:Ada D. Sarmento Re: Arcadia Biosciences, Inc. Registration Statement on Form S-1 (No. 333-235446) Request for Acceleration Dear Ms. Sarmento: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Arcadia Biosciences, Inc. hereby requests that the effective date of its Registration Statement on Form S-1 (File No. 333-235446) be accelerated so that the same will become effective at 4:00 p.m., Eastern Time, on Friday, December 20, 2019, or as soon thereafter as practicable. If you have any questions regarding this request or the Registration Statement, please call our counsel Mike De Angelis of Weintraub Tobin, at (916) 558-6164. Very truly yours, Arcadia Biosciences, Inc. By: /s/ Pam Haley Pam Haley Chief Financial Officer